Business, energy, technology, markets and global industry news from Business News Today

amyotrophic lateral sclerosis

PharmaDeviceNews amyotrophic lateral sclerosis
Representative image: Alchemab Therapeutics’ £25 million funding supports AI-enabled antibody discovery, Resiliome expansion and new clinical programs.
Pharma & Biotech

Why British Business Bank just made its biggest life sciences bet on Alchemab Therapeutics

Alchemab Therapeutics secures £25 million to double its antibody data and advance two wholly owned programs toward clinical development.

Read More
Representative image: Laboratory research into AP-101 highlights AL-S Pharma’s effort to target misfolded SOD1 and advance a potential new treatment approach for amyotrophic lateral sclerosis.
Pharma & Biotech

AL-S Pharma’s AP-101 Phase 2 data strengthen the misfolded SOD1 strategy in ALS

Read how AL-S Pharma’s AP-101 Phase 2 data strengthen the misfolded SOD1 case in ALS and what its Phase 3 trial must prove.

Read More
Representative image: A clinician reviews patient data in an ALS research setting as Shionogi expands real-world evidence collection through its NeuroBANK partnership.
Pharma & Biotech

Shionogi deepens ALS real-world data strategy after $2.5bn Radicava acquisition

Read how Shionogi’s NeuroBANK partnership could shape Radicava evidence, ALS trial design and real-world treatment research.

Read More
Pharma & Biotech

Coya Therapeutics advances COYA 302 as FDA fast track status raises clinical expectations

Coya Therapeutics’ COYA 302 fast track status raises the stakes for Treg-based ALS therapy. Find out what comes next.

Read More
Pharma & Biotech

What Clene Inc.’s FDA feedback reveals about the future of surrogate endpoints in ALS trials

Can biomarker-driven approvals transform ALS drug development? Explore how Clene Inc.’s FDA feedback on CNM-Au8 could accelerate innovation.

Read More
Representative image: Corcept Therapeutics’ dazucorilant survival signal in amyotrophic lateral sclerosis highlights how ALS clinical trials are shifting attention from short-term functional scores to longer-term survival outcomes.
Pharma & Biotech

A failed ALS trial still showed a stunning survival signal. Can Corcept turn it into Phase 3 proof?

A failed ALS endpoint meets a striking survival signal. Corcept now faces the harder test: proving dazucorilant in Phase 3.

Read More
Pharma & Biotech

What Celosia Therapeutics’ Phase 1b CTx1000 trial could reveal about TDP-43 targeting in ALS

Celosia Therapeutics has dosed the first ALS patient with CTx1000. Read why this TDP-43 gene therapy trial could reshape the ALS pipeline.

Read More
Pharma & Biotech

Can STATHMIN-2 restoration succeed where ALS therapies have failed? QurAlis data examined

QurAlis ANQUR trial data puts STATHMIN-2 restoration on the ALS map. Find out what changes and what risks remain.

Read More
Pharma & Biotech

Coya Therapeutics expands ALS trial into Canada as COYA 302 gains Health Canada clearance

Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.

Read More
Representative image depicting the neurological basis of amyotrophic lateral sclerosis (ALS), highlighting motor neuron degeneration and cortical hyperexcitability. This visual supports our coverage of QurAlis’ Kv7.2/7.3-targeted therapy QRL-101 and its implications in ALS drug development.
Pharma & Biotech

QurAlis links QRL-101 to motor nerve excitability shift in ALS: Is target validation finally here?

QurAlis confirms target engagement of QRL-101 in ALS patients. Find out what this means for epilepsy trials and Kv7-targeted drug development.

Read More